Daewoong Pharmaceutical Co., Ltd (KRX: 069620)
South Korea
· Delayed Price · Currency is KRW 127,500
-3,500 (-2.67%)
Nov 18, 2024, 3:30 PM KST
Daewoong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,399,052 | 1,375,329 | 1,280,092 | 1,152,976 | 1,055,424 | 1,113,426 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | 0 | Upgrade
|
| Revenue | 1,399,052 | 1,375,329 | 1,280,092 | 1,152,976 | 1,055,424 | 1,113,426 | Upgrade
|
| Revenue Growth (YoY) | 5.01% | 7.44% | 11.03% | 9.24% | -5.21% | 7.95% | Upgrade
|
| Cost of Revenue | 691,884 | 688,221 | 641,997 | 609,227 | 609,435 | 635,992 | Upgrade
|
| Gross Profit | 707,168 | 687,108 | 638,095 | 543,749 | 445,989 | 477,434 | Upgrade
|
| Selling, General & Admin | 389,215 | 376,109 | 366,091 | 315,434 | 299,358 | 310,304 | Upgrade
|
| Research & Development | 170,305 | 171,573 | 163,602 | 127,269 | 115,218 | 109,441 | Upgrade
|
| Other Operating Expenses | 4,450 | 4,382 | 4,297 | 3,554 | 3,531 | 3,471 | Upgrade
|
| Operating Expenses | 578,606 | 565,990 | 542,297 | 455,020 | 429,009 | 432,746 | Upgrade
|
| Operating Income | 128,563 | 121,118 | 95,797 | 88,729 | 16,980 | 44,687 | Upgrade
|
| Interest Expense | -7,586 | -13,603 | -8,406 | -10,248 | -10,610 | -10,088 | Upgrade
|
| Interest & Investment Income | 3,576 | 3,099 | 4,135 | 2,569 | 3,423 | 2,727 | Upgrade
|
| Earnings From Equity Investments | 28,731 | 29,977 | -374.54 | 257.52 | -355.37 | -22.16 | Upgrade
|
| Currency Exchange Gain (Loss) | 891.29 | -1,705 | -40.31 | 3,246 | -6,548 | 2,177 | Upgrade
|
| Other Non Operating Income (Expenses) | -44,502 | -13,423 | -43,639 | -69,962 | 8,622 | -6,880 | Upgrade
|
| EBT Excluding Unusual Items | 109,672 | 125,462 | 47,473 | 14,591 | 11,511 | 32,601 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,078 | 130.67 | -4,171 | 8,308 | 2,622 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1,221 | -1,221 | 246.4 | -1,029 | 7,530 | 42.2 | Upgrade
|
| Asset Writedown | -2,372 | -2,372 | -5,219 | -2,109 | -8,103 | -9,322 | Upgrade
|
| Pretax Income | 105,000 | 121,999 | 38,330 | 19,761 | 13,559 | 23,322 | Upgrade
|
| Income Tax Expense | 20,934 | 1,996 | -833.51 | -10,323 | -10,589 | -5,544 | Upgrade
|
| Earnings From Continuing Operations | 84,066 | 120,003 | 39,163 | 30,084 | 24,148 | 28,866 | Upgrade
|
| Minority Interest in Earnings | 6,807 | 1,736 | 3,076 | -5,578 | -11,395 | -6,860 | Upgrade
|
| Net Income | 90,872 | 121,739 | 42,240 | 24,506 | 12,753 | 22,006 | Upgrade
|
| Net Income to Common | 90,872 | 121,739 | 42,240 | 24,506 | 12,753 | 22,006 | Upgrade
|
| Net Income Growth | 77.12% | 188.21% | 72.37% | 92.15% | -42.05% | - | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 11 | 11 | 11 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 11 | 11 | 11 | 10 | Upgrade
|
| Shares Change (YoY) | 2.68% | 3.21% | 0.59% | 3.21% | 3.31% | - | Upgrade
|
| EPS (Basic) | 7897.50 | 10656.06 | 3815.95 | 2226.87 | 1196.10 | 2132.18 | Upgrade
|
| EPS (Diluted) | 7897.50 | 10656.06 | 3815.95 | 2226.87 | 1196.10 | 2132.18 | Upgrade
|
| EPS Growth | 72.49% | 179.25% | 71.36% | 86.18% | -43.90% | - | Upgrade
|
| Free Cash Flow | -68,433 | 26,671 | 52,988 | 10,906 | 74,495 | 35,286 | Upgrade
|
| Free Cash Flow Per Share | -5947.35 | 2334.57 | 4786.97 | 991.08 | 6986.64 | 3418.88 | Upgrade
|
| Dividend Per Share | 600.000 | 600.000 | - | - | - | - | Upgrade
|
| Gross Margin | 50.55% | 49.96% | 49.85% | 47.16% | 42.26% | 42.88% | Upgrade
|
| Operating Margin | 9.19% | 8.81% | 7.48% | 7.70% | 1.61% | 4.01% | Upgrade
|
| Profit Margin | 6.50% | 8.85% | 3.30% | 2.13% | 1.21% | 1.98% | Upgrade
|
| Free Cash Flow Margin | -4.89% | 1.94% | 4.14% | 0.95% | 7.06% | 3.17% | Upgrade
|
| EBITDA | 175,076 | 164,915 | 135,492 | 129,613 | 57,861 | 84,882 | Upgrade
|
| EBITDA Margin | 12.51% | 11.99% | 10.58% | 11.24% | 5.48% | 7.62% | Upgrade
|
| D&A For EBITDA | 46,514 | 43,797 | 39,695 | 40,883 | 40,882 | 40,195 | Upgrade
|
| EBIT | 128,563 | 121,118 | 95,797 | 88,729 | 16,980 | 44,687 | Upgrade
|
| EBIT Margin | 9.19% | 8.81% | 7.48% | 7.70% | 1.61% | 4.01% | Upgrade
|
| Effective Tax Rate | 19.94% | 1.64% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 79,245 | 80,587 | 59,081 | 51,192 | 73,841 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.